Health 31 May 2026 Daily Monitor (Uganda)
J&J's Erleada Shows Significant Promise in Reducing Prostate Cancer Spread and Death
A new late-stage study reveals that Johnson & Johnson's drug Erleada, when combined with hormone therapy, significantly improves outcomes for men with high-risk prostate cancer. The treatment regimen led to substantially higher rates of undetectable cancer post-surgery and reduced the risk of disease progression or death. Source: https://www.monitor.co.ug/uganda/magazines/healthy-living/j-j-drug-reduces-risk-of-prostate-cancer-spread-and-death-in-late-stage-study-5480024
Johnson & Johnson’s prostate cancer medication, Erleada (apalutamide), has demonstrated a notable improvement in patient outcomes during a recent late-stage clinical trial. When administered in conjunction with standard hormone-blocking therapy, both before and after prostate surgery, Erleada significantly enhanced the chances of eradicating the cancer. The study results, which tracked patients for over five years, indicated that this combination therapy led to a nine-fold increase in the likelihood of having little to no detectable cancer at the time of surgery, compared to relying on hormone therapy alone.
Furthermore, the addition of Erleada to the treatment regimen reduced the risk of the cancer spreading to other parts of the body or resulting in death by 20%. These findings, presented at the American Society of Clinical Oncology meeting, are poised to influence the standard approach to treating men diagnosed with high-risk localized or locally advanced prostate cancer. Currently, surgical removal of the prostate and radiation therapy are the primary treatments for these patients.
For a subset of patients who underwent a full year of combination therapy, the time before requiring further treatment was extended to over six years, almost double the duration seen with hormone therapy alone. This extended treatment also lowered the risk of cancer recurrence and death by 29%. This is a significant development, as nearly half of patients undergoing current standard treatments see their cancer return.
Erleada functions as an androgen receptor pathway inhibitor, obstructing the signals that fuel prostate cancer growth. Experts suggest these results could be “paradigm-changing” for the treatment of localized, high-risk prostate cancer, as no drugs in its class are currently approved for this specific indication alongside surgery or radiation. The safety profile of the Erleada combination was consistent with previous studies, with common side effects including hot flushes, urinary incontinence, and erectile dysfunction. Johnson & Johnson plans to seek regulatory approval for this combination therapy in earlier stages of prostate cancer globally.
For more details, refer to the Daily Monitor.